JAK1 OVEREXPRESSION

CI-VAR-00003027Explore in graph →CIViC 396

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
JAK1 OVEREXPRESSION	Enzastaurin	Predictive	D	Supports Sensitivity Response	4	accepted	EID931 Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance. Overexpr… (full text at CIViC) PMID 22333600 · Shimokawa et al., 2012 · Open in CIViC	civic
Sarcoma1
JAK1 OVEREXPRESSION	Ruxolitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7852 Sequencing of an 8-year old patient diagnosed with a left tentorial-based CNS sarcoma discovered an EWSR1-ATF fusion and IL6 and JAK1 overexpression. Patient was treated with ruxolitinib based on over… (full text at CIViC) PMID 31372595 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.